Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shenqigui
- Development stage
- Phase 4
- Lead developer
- Chengdu First Pharmaceutical
- Administration
- Oral
01
Overview
Shenqigui is an oral liquid that is being investigated for its potential to improve bone marrow suppression in patients with small cell lung cancer who are undergoing chemotherapy. Specifically, it targets patients diagnosed with a Qi and yin deficiency type. This traditional Chinese medicine-based intervention is developed by Chengdu First Pharmaceutical Co. LTD and Chengdu University of Traditional Chinese Medicine and is administered orally.
- Brand names
- Shen-Qi-Gui
- Other names
- Shenqigui oral liquid肾气归口服液
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)JUN (Transcription factor Jun)JNK (Mitogen-activated protein kinase kinase kinase family)MYC (MYC proto-oncogene protein)GR (Glucocorticoid receptor)IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on shenqigui.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on shenqigui.